These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 9286756)
1. Decreased beta-isomerization of the C-terminal telopeptide of type I collagen alpha 1 chain in Paget's disease of bone. Garnero P; Fledelius C; Gineyts E; Serre CM; Vignot E; Delmas PD J Bone Miner Res; 1997 Sep; 12(9):1407-15. PubMed ID: 9286756 [TBL] [Abstract][Full Text] [Related]
2. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease. Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094 [TBL] [Abstract][Full Text] [Related]
3. Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone. Alexandersen P; Peris P; Guañabens N; Byrjalsen I; Alvarez L; Solberg H; Cloos PA J Bone Miner Res; 2005 Apr; 20(4):588-95. PubMed ID: 15765177 [TBL] [Abstract][Full Text] [Related]
4. Effect of surgical menopause and Paget's disease of bone on the isomerization of type I collagen carboxyterminal telopeptide: evolution after antiresorptive therapy. Peris P; Alvarez L; Monegal A; Guañabens N; Durán M; Echevarría M; Ros I; Ballesta AM; Muñoz-Gómez J J Bone Miner Metab; 2002; 20(2):116-20. PubMed ID: 11862534 [TBL] [Abstract][Full Text] [Related]
5. Investigation of bone disease using isomerized and racemized fragments of type I collagen. Cloos PA; Fledelius C; Christgau S; Christiansen C; Engsig M; Delmas P; Body JJ; Garnero P Calcif Tissue Int; 2003 Jan; 72(1):8-17. PubMed ID: 12384813 [TBL] [Abstract][Full Text] [Related]
6. Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study. Garnero P; Cloos P; Sornay-Rendu E; Qvist P; Delmas PD J Bone Miner Res; 2002 May; 17(5):826-33. PubMed ID: 12009013 [TBL] [Abstract][Full Text] [Related]
7. Collagen fragments in urine derived from bone resorption are highly racemized and isomerized: a biological clock of protein aging with clinical potential. Cloos PA; Fledelius C Biochem J; 2000 Feb; 345 Pt 3(Pt 3):473-80. PubMed ID: 10642504 [TBL] [Abstract][Full Text] [Related]
8. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease. Alvarez L; Guañabens N; Peris P; Monegal A; Bedini JL; Deulofeu R; Martinez de Osaba MJ; Muñoz-Gomez J; Rivera-Fillat F; Ballesta AM J Bone Miner Res; 1995 Mar; 10(3):458-65. PubMed ID: 7785468 [TBL] [Abstract][Full Text] [Related]
9. Bone turnover and type I collagen C-telopeptide isomerization in adult osteogenesis imperfecta: associations with collagen gene mutations. Garnero P; Schott AM; Prockop D; Chevrel G Bone; 2009 Mar; 44(3):461-6. PubMed ID: 19071236 [TBL] [Abstract][Full Text] [Related]
10. Biochemical markers of bone turnover in Paget's disease of bone. Delmas PD J Bone Miner Res; 1999 Oct; 14 Suppl 2():66-9. PubMed ID: 10510216 [TBL] [Abstract][Full Text] [Related]
11. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices. Woitge HW; Pecherstorfer M; Li Y; Keck AV; Horn E; Ziegler R; Seibel MJ J Bone Miner Res; 1999 May; 14(5):792-801. PubMed ID: 10320528 [TBL] [Abstract][Full Text] [Related]
12. Biochemical assessment of Paget's disease of bone. Shankar S; Hosking DJ J Bone Miner Res; 2006 Dec; 21 Suppl 2():P22-7. PubMed ID: 17229003 [TBL] [Abstract][Full Text] [Related]
13. Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis. Charni N; Juillet F; Garnero P Arthritis Rheum; 2005 Apr; 52(4):1081-90. PubMed ID: 15818703 [TBL] [Abstract][Full Text] [Related]
14. Isoaspartyl bond formation within N-terminal sequences of collagen type I: implications for their use as markers of collagen degradation. Brady JD; Ju J; Robins SP Clin Sci (Lond); 1999 Feb; 96(2):209-15. PubMed ID: 9918902 [TBL] [Abstract][Full Text] [Related]
16. Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen. Bonde M; Garnero P; Fledelius C; Qvist P; Delmas PD; Christiansen C J Bone Miner Res; 1997 Jul; 12(7):1028-34. PubMed ID: 9200001 [TBL] [Abstract][Full Text] [Related]
17. Increased cartilage type II collagen degradation in patients with osteogenesis imperfecta used as a human model of bone type I collagen alterations. Rousseau JC; Chevrel G; Schott AM; Garnero P Bone; 2010 Apr; 46(4):897-900. PubMed ID: 20005316 [TBL] [Abstract][Full Text] [Related]
18. Urinary excretion of hydroxylysine and its glycosides as an index of collagen degradation. Krane SM; Kantrowitz FG; Byrne M; Pinnell SR; Singer FR J Clin Invest; 1977 May; 59(5):819-27. PubMed ID: 404321 [TBL] [Abstract][Full Text] [Related]
19. Racemization and isomerization of type I collagen C-telopeptides in human bone and soft tissues: assessment of tissue turnover. Gineyts E; Cloos PA; Borel O; Grimaud L; Delmas PD; Garnero P Biochem J; 2000 Feb; 345 Pt 3(Pt 3):481-5. PubMed ID: 10642505 [TBL] [Abstract][Full Text] [Related]
20. Cross-sectional evaluation of bone metabolism in men. Szulc P; Garnero P; Munoz F; Marchand F; Delmas PD J Bone Miner Res; 2001 Sep; 16(9):1642-50. PubMed ID: 11547833 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]